Volume | 1,375,989 |
|
|||||
News | - | ||||||
Day High | 40.34 | Low High |
|||||
Day Low | 36.335 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Vera Therapeutics Inc | VERA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
39.51 | 36.335 | 40.34 | 38.00 | 39.48 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,004 | 1,375,989 | $ 38.07 | $ 52,389,372 | - | 6.07 - 50.78 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:46:40 | 1 | $ 38.00 | USD |
Vera Therapeutics (VERA) Options Flow Summary
Vera Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.69B | 44.43M | - | 0 | -95.99M | -2.16 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Vera Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VERA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 48.70 | 50.65 | 36.335 | 44.30 | 1,346,805 | -10.70 | -21.97% |
1 Month | 42.57 | 50.65 | 35.855 | 43.18 | 1,215,461 | -4.57 | -10.74% |
3 Months | 27.10 | 50.78 | 26.90 | 41.44 | 1,264,486 | 10.90 | 40.22% |
6 Months | 10.26 | 50.78 | 9.24 | 31.36 | 991,590 | 27.74 | 270.37% |
1 Year | 6.32 | 50.78 | 6.07 | 24.89 | 792,433 | 31.68 | 501.27% |
3 Years | 11.41 | 50.78 | 5.20 | 20.70 | 398,415 | 26.59 | 233.04% |
5 Years | 11.41 | 50.78 | 5.20 | 20.70 | 398,415 | 26.59 | 233.04% |
Vera Therapeutics Description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |